AMD, Absci

Absci Stock Jumps As AMD Invests $20M To Boost AI Drug Discovery
AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the company entered into a strategic collaboration with Advanced Micro Devices Inc (NASDAQ:AMD) to enhance its AI drug discovery capabilities.
AMD invests $20 million in AI drug research at Vancouver-based Absci
Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial intelligence to develop new drug therapies.
AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips
The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other industries.
AMD invests $20M in AI-powered drug discovery company Absci
Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop new hardware and software optimized for the healthcare sector. The effort will place particular emphasis on developing technologies that can advance drug discovery.
AMD Invests in Absci to Strengthen AI Chip Presence in Drug Discovery
In a strategic move to expand its footprint in the healthcare sector, Advanced Micro Devices (AMD) has announced a $20 million investment in Absci, a Washington-based drug-discovery company. This investment not only highlights AMD’s ambition to diversify its market presence but also emphasizes the growing role of artificial intelligence (AI) in revolutionizing life sciences.
Absci stock soars on AMD partnership and investment
Investing.com -- Shares of Absci Corporation (NASDAQ: ABSI) soared 50% following the announcement of a strategic collaboration and a $20 million investment from AMD (NASDAQ: AMD ). The partnership aims to enhance Absci's AI-driven drug discovery capabilities using AMD's Instinct accelerators and ROCm software.
Absci, AMD announce collaboration, strategic investment
Absci Corporation (ABSI) announced a strategic collaboration with AMD (AMD) to deploy AMD Instinct accelerators and ROCm software to power
AbSci’s Strategic Growth Bolstered by AMD Collaboration and Promising Pipeline Advancements
Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on AbSci (ABSI – Research Report) and keeping the price target at ...
AMD Shares Slide as HSBC Downgrades Stock Over Nvidia Concerns; Absci Collaboration Announced
Following HSBC downgrading of the semiconductor company's stock, Advanced Micro Devices ( AMD, Financials) shares fell over 5 ...
AMD is going head-to-head with Nvidia in AI-backed drug discovery with new deal
Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.
Absci price target lowered to $5 from $6 at KeyBanc
KeyBanc lowered the firm’s price target on Absci (ABSI) to $5 from $6 and keeps an Overweight rating on the shares. The firm notes healthcare ...
Absci rises after report on $20M investment by Advanced Micro Devices
Absci (NASDAQ:ABSI) was rising after a media report about the semiconductor company Advanced Micro Devices (NASDAQ:AMD) ...
Absci Shares Rise 27% on Report of $20 Mln Investment from Advanced Micro Devices
Shares of Absci on Wednesday jumped following a report on a $20 million investment from Advanced Micro Devices. The stock was up 27% to $3.89 in pre-market trading. Through Tuesday's close, shares ...
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics ...